Metabolic disorders and the risk of COVID-19
https://doi.org/10.18699/SSMJ20220101
Abstract
In the present review the analysis of the world literature devoted to the study of metabolic disorders in the body and the risk of COVID-19 disease. It is known that metabolic syndrome is an independent risk factor for the severe course of new coronavirus infection. This review summarizes data on the mechanisms of metabolic dysfunction in a new coronavirus infection, analyzes the results of studies that investigated the issues of associations between the course of COVID-19 and various metabolic disorders, such as hyperglycemia and diabetes mellitus, dyslipidemia, obesity, non-alcoholic fatty liver disease, their severity, potential targets of therapy, predictors of the development of a severe course of new coronavirus infection are considered. These metabolic disorders increase the impairment of the immune system and make patients more susceptible to the development of infectious diseases, in particular, to infection with a new coronavirus infection. Taking into account the obtained data, it becomes obvious the need to identify and monitor patients with pre-existing metabolic diseases, as well as their development during and after COVID-19. The information on the topic from publications based on PubMed, PubMed Central, Scopus, Google Scholar, Medscape, UpYoDate, eLIBRARY.RU data were used.
Keywords
COVID-19,
new coronavirus infection,
metabolic syndrome,
obesity,
hyperglycemic,
diabetes mellitus,
dyslipidemia,
non-alcoholic fatty liver disease,
metabolic dysfunction-associated fatty liver disease.
Supporting agencies: This work was carried out within the framework of the budget theme No. AAAA-A19-119101490005-5 “Formation of cohorts of children, adolescents, young people to study the mechanisms and characteristics of the human life cycle in the Russian population”.
About the Authors
A. A. Karaseva
Research Institute of Internal and Preventive Medicine – Branch of the Institute of Cytology and Genetics of Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
Aleksandra A. Karaseva
630089, Novosibirsk, Boris Bogatkov str., 175/1
A. D. Khudyakova
Research Institute of Internal and Preventive Medicine – Branch of the Institute of Cytology and Genetics of Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
Alena D. Khudyakova, candidate of medical sciences
630089, Novosibirsk, Boris Bogatkov str., 175/1
Yu. I. Ragino
Research Institute of Internal and Preventive Medicine – Branch of the Institute of Cytology and Genetics of Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
Yuliya I. Ragino, doctor of medical sciences, professor, corresponding member RAS
630089, Novosibirsk, Boris Bogatkov str., 175/1
References
1. Weekly epidemiological update on COVID-19 23 November 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-23-november-2021
2. WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. Available from: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefingon-2019-ncov-on-11-february-2020
3. Guan W.J., Liang W.H., Zhao Y., Liang H.R., Chen Z.S., Li Y.M., Liu X.Q., Chen R.C., Tang C.L., Wang T., … China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur. Respir. J. 2020;5(5):2000547. doi: 10.1183/13993003.00547-2020
4. Gao F., Zheng K.I., Wang X.B., Yan H.D., Sun Q.F., Pan K.H., Wang T.Y., Chen Y.P., George J., Zheng M.H. Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. J. Gastroenterol. Hepatol. 2021;36(1):204–207. doi: 10.1111/jgh.15112
5. Petrilli C.M., Jones S.A., Yang J., Rajagopalan H., O’Donnell L., Chernyak Y., Tobin K.A., Cerfolio R.J., Francois F., Horwitz L.I. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020; 369:m1966. doi: 10.1136/bmj.m1966
6. Chai X., Hu L., Zhang Y., Han W., Lu Z., Ke A., Zhou J., Shi G., Fang N., Fan J., Cai J., Fan J., Lan F. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020.02.03.931766. doi: 10.1101/2020.02.03.931766
7. Portincasa P., Krawczyk M., Smyk W., Lammert F., di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics. Eur. J. Clin. Invest. 2020;50(10):e13338. doi: 10.1111/eci.13338
8. Moser J.S., Galindo-Fraga A., Ortiz-Hernández A.A., Gu W., Hunsberger S., Galán-Herrera J.F., Guerrero M.L., Ruiz-Palacios G.M., Beigel J.H.; La Red ILI 002 Study Group. Underweight, overweight, and obesity as independent risk factors for hospitalization in adults and children from influenza and other respiratory viruses. Influenza Other Respir. Viruses. 2019;13(1):3–9. doi: 10.1111/irv.12618
9. Jia X., Yin C., Lu S., Chen Y., Liu Q., Bai J., Lu Y. Two things about COVID-19 might need attention. Preprints. 2020:2020020315. doi: 10.20944/preprints202002.0315.v1
10. Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., Davidson K.W.; the Northwell COVID-19 Research Consortium, Barnaby D.P., Becker L.B., Chelico J.D., … Zanos T.P. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA. 2020;323(20):2052–2059. doi: 10.1001/jama.2020.6775
11. ICNARC Report on COVID-19 in Critical Care. 2020. Available from: www.icnarc.og.
12. Lighter J., Phillips M., Hochman S., Sterling S., Johnson D., Francois F., Stachel A. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin. Infect. Dis. 2020;71(15):896–897. doi: 10.1093/cid/ciaa415
13. Tartof S.Y., Qian L., Hong V., Wei R., Nadjafi R.F., Fischer H., Li Z., Shaw S.F., Caparosa S.L., Nau C.L., … Murali S.B. Obesity and mortality among patients diagnosed with COVID-19: results from an Integrated Health Care Organization. Ann. Intern. Med. 2020;173(10):773–781. doi: 10.7326/M20-3742
14. Giacomelli A., Ridolfo A.L., Milazzo L., Oreni L., Bernacchia D., Siano M., Bonazzetti C., Covizzi A., Schiuma M., Passerini M., … Galli M. 30day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study. Pharmacol. Res. 2020;158:104931. doi: 10.1016/j.phrs.2020.104931
15. Yu W., Rohli K.E., Yang S., Jia P. Impact of obesity on COVID-19 patients. Diabetes Complications. 2021;35(3):107817. doi: 10.1016/j.jdiacomp.2020.107817
16. Cabandugama P.K., Gardner M.J., Sowers J.R. The renin angiotensin aldosterone system in obesity and hypertension: roles in the cardiorenal metabolic syndrome. Med. Clin. North. Am. 2017;101(1):129–137. doi: 10.1016/j.mcna.2016.08.009
17. Shestakova M.V. The role of the tissue renin-angiotensin-aldosterone system in the development of metabolic syndrome, diabetes mellitus and itsvascular complications. Sakharnyy diabet = Diabetes Mellitus. [In Russian]. 2010;13(3):14–19. doi: 10.14341/20720351-5481
18. Liu Y., Yang Y., Zhang C., Huang F., Wang F., Yuan J., Wang Z., Li J., Li J., Feng C., … Liu L. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci. China. Life Sci. 2020;63(3):364–374. doi: 10.1007/s11427020-1643-8
19. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet. 2005;365(16-22):1415– 1428. doi: 10.1016/S0140-6736(05)66378-7
20. Blot M., Masson D., Nguyen M., Bourredjem A.; LYMPHONIE Study Group, Binquet C., Piroth L. Are adipokines the missing link between obesity, immune response, and outcomes in severe COVID-19? Int. J. Obes. (Lond). 2021;45(9):2126–2131. doi: 10.1038/s41366-021-00868-5
21. Rebello C.J., Kirwan J.P., Greenway F.L. Obesity, the most common comorbidity in SARS-CoV-2: is leptin the link? Int. J. Obes. (Lond). 2020;44(9):1810– 1817. doi: 10.1038/s41366-020-0640-5
22. Popkin B.M., Du S., Green W.D., Beck M.A., Algaith T., Herbst C.H., Alsukait R.F., Alluhidan M., Alazemi N., Shekar M. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obes. Rev. 2020; 21(11):e13128. doi: 10.1111/obr.13128
23. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W.Jr. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003;112(12):1796–1808. doi: 10.1172/JCI19246
24. Francisco V., Pino J., Campos-Cabaleiro V., Ruiz-Fernández C., Mera A., Gonzalez-Gay M.A., Gómez R., Gualillo O. Obesity, fat mass and immune system: role for leptin. Front. Physiol. 2018;9:640. doi: 10.3389/fphys.2018.00640
25. Zhu L., She Z.G., Cheng X., Qin J.J., Zhang X.J., Cai J., Lei F., Wang H., Xie J., Wang W., … Li H. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068–1077.e3. doi: 10.1016/j.cmet.2020.04.021
26. Bornstein S.R., Rubino F., Khunti K., Mingrone G., Hopkins D., Birkenfeld A.L., Boehm B., Amiel S., Holt R.I., Skyler J.S., … Ludwig B. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546–550. doi: 10.1016/S22138587(20)30152-2
27. Sheetz M.J., King G.L. Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA. 2002;288(20):2579–2588. doi: 10.1001/jama.288.20.2579
28. Yang Y., Cai Z., Zhang J. Hyperglycemia at admission is a strong predictor of mortality and severe/ critical complications in COVID-19 patients: a metaanalysis. Biosci. Rep. 2021;41(2): BSR20203584. doi: 10.1042/BSR20203584
29. Guo W., Li M., Dong Y., Zhou H., Zhang Z., Tian C., Qin R., Wang H., Shen Y., Du K., Zhao L., Fan H., Luo S., Hu D. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab. Res. Rev. 2020;36(7):e3319. doi: 10.1002/dmrr.3319
30. Hojyo S., Uchida M., Tanaka K., Hasebe R., Tanaka Y., Murakami M., Hirano T. How COVID-19 induces cytokine storm with high mortality. Inflamm. Regen. 2020;40:37. doi: 10.1186/s41232-020-00146-3
31. Herold T., Jurinovic V., Arnreich C., Lipworth B.J., Hellmuth J.C., von Bergwelt-Baildon M., Klein M., Weinberger T. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J. Allergy Clin. Immunol. 2020;146(1):128–136.e4. doi: 10.1016/j.jaci.2020.05.008
32. Zhu Z., Mao Y., Chen G. Predictive value of HbA1c for in-hospital adverse prognosis in COVID-19: A systematic review and meta-analysis. Prim. Care Diabetes. 2021;15(6):910–917. doi: 10.1016/j.pcd.2021.07.013
33. Yang J.K., Lin S.S., Ji X.J., Guo L.M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193– 199. doi: 10.1007/s00592-009-0109-4
34. Bindom S.M., Lazartigues E. The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol. Cell. Endocrinol. 2009;302(2):193–202. doi: 10.1016/j.mce.2008.09.020
35. Shrestha D.B., Budhathoki P., Raut S., Adhikari S., Ghimire P., Thapaliya S., Rabaan A.A., Karki B.J. New-onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis. World J. Virol. 2021;10(5):275–287. doi: 10.5501/wjv.v10.i5.275
36. Xu L., Liu J., Lu M., Yang D., Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver. Int. 2020;40(5):998–1004. doi: 10.1111/ liv.14435
37. Huang R., Zhu L., Wang J., Xue L., Liu L., Yan X., Huang S., Li Y., Yan X., Zhang B., … Wu C. Clinical features of COVID-19 patients with non-alcoholic fatty liver disease. Hepatol. Commun. 2020;4(12):1758–1768. doi: 10.1002/hep4.1592
38. Ji D., Qin E., Xu J., Zhang D., Cheng G., Wang Y., Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J. Hepatol. 2020;73(2):451–453. doi: 10.1016/j.jhep.2020.03.044
39. Cai Q., Huang D., Yu H., Zhu Z., Xia Z., Su Y., Li Z., Zhou G., Gou J., Qu J., … Xu L. COVID-19: Abnormal liver function tests. J. Hepatol. 2020;73(3):566– 574. doi: 10.1016/j.jhep.2020.04.006
40. Karaseva A.A., Evdokimova N.E., Khudyakova A.D., Striukova E.V., Volkova M.V., Logvinenko I.I. Non-alcoholic fatty liver disease and metabolic liver dysfunction in the new coronavirus infection COVID-19. Sibirskiy nauchnyy meditsinskiy zhurnal = Siberian Scientific Medical Journal. 2021;41(6):68–75. [In Russian]. doi: 10.18699/SSMJ20210608
41. Zheng K.I., Gao F., Wang X.B., Sun Q.F., Pan K.H., Wang T.Y., Ma H.L., Chen Y.P., Liu W.Y., George J., Zheng M.H. Letter to the editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020;108:154244. doi: 10.1016/j.metabol.2020.154244
42. Roca-Fernández A., Dennis A., Nicholls R., McGonigle J., Kelly M., Banerjee R., Banerjee A., Sanyal A.J. Hepatic steatosis, rather than underlying obesity, increases the risk of infection and hospitalization for COVID-19. Front. Med. (Lausanne). 2021;8:636637. doi: 10.3389/fmed.2021.636637
43. Tignanelli C.J., Bramante C.T., Dutta N., Tamariz L., Usher M.G., Ikramuddin S. Metabolic surgery may protect against admission for COVID-19 in persons with nonalcoholic fatty liver disease. Surg. Obes. Relat. Dis. 2021;17(10):1780–1786. doi: 10.1016/j.soard.2021.05.029
44. Zuin M., Rigatelli G., Bilato C., Cervellati C., Zuliani G., Roncon L. Prognostic role of metabolic syndrome in COVID-19 patients: a systematic review meta-analysis. Viruses. 2021;13(10):1938. doi: 10.3390/v13101938
45. Lorizate M., Kräusslich H.G. Role of lipids in virus replication. Cold Spring Harb. Perspect. Biol. 2011;3(10):a004820. doi: 10.1101/cshperspect. a004820
46. Cirstea M., Walley K.R., Russell J.A., Brunham L.R., Genga K.R., Boyd J.H. Decreased high-density lipoprotein cholesterol level is an early prognostic marker for organ dysfunction and death in patients with suspected sepsis. J. Crit. Care. 2017;38:289–294. doi: 10.1016/j.jcrc.2016.11.041
47. Hardt M., Schwudke D., Neuman B.W., Pleschka S., Ziebuhr J. Inhibition of cytosolic phospholipase A2α impairs an early step of coronavirus replication in cell culture. J. Virol. 2018;92(4):e01463–17. doi: 10.1128/JVI.01463-17
48. Barberis E., Timo S., Amede E., Vanella V.V., Puricelli C., Cappellano G., Raineri D., Cittone M.G., Rizzi E., Pedrinelli A.R., … Manfredi M. Large-scale plasma analysis revealed new mechanisms and molecules associated with the host response to SARSCoV-2. Int. J. Mol. Sci. 2020;21(22):8623. doi: 10.3390/ijms21228623
49. Bock J.O., Ortea I. Re-analysis of SARS-CoV2-infected host cell proteomics time-course data by impact pathway analysis and network analysis: a potential link with inflammatory response. Aging (Albany NY). 2020;12(12):11277–11286. doi: 10.18632/aging.103524
50. Abu-Farha M., Thanaraj T.A., Qaddoumi M.G., Hashem A., Abubaker J., Al-Mulla F. The role of lipid metabolism in COVID-19 virus infection and as a drug target. Int. J. Mol. Sci. 2020;21(10):3544. doi: 10.3390/ijms21103544
51. Mahat R.K., Rathore V., Singh N., Singh N., Singh S.K., Shah R.K., Garg C. Lipid profile as an indicator of COVID-19 severity: A systematic review and meta-analysis. Clin. Nutr. ESPEN. 2021;45:91–101. doi: 10.1016/j.clnesp.2021.07.023
52. Hu X., Chen D., Wu L., He G., Ye W. Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection. Clin. Chim. Acta. 2020;510:105–110. doi: 10.1016/j.cca.2020.07.015
53. Zuin M., Rigatelli G., Bilato C., Cervellati C., Zuliani G., Roncon L. Dyslipidaemia and mortality in COVID-19 patients: a meta-analysis. QJM. 2021;114(6):390–397. doi: 10.1093/qjmed/hcab071
54. Kim J.A., Montagnani M., Chandrasekran S., Quon M.J. Role of lipotoxicity in endothelial dysfunction. Heart Fail. Clin. 2012;8(4):589–607. doi: 10.1016/j. hfc.2012.06.012
55. Froldi G., Dorigo P. Endothelial dysfunction in Coronavirus disease 2019 (COVID-19): Gender and age influences. Med. Hypotheses. 2020;144:110015. doi: 10.1016/j.mehy.2020.110015
56. Kaji H. High-density lipoproteins and the immune system. J. Lipids. 2013;2013:684903. doi: 10.1155/2013/684903
57. McKechnie J.L., Blish C.A. The innate immune system: fighting on the front lines or fanning the flames of COVID-19? Cell Host Microbe. 2020;27(6):863– 869. doi: 10.1016/j.chom.2020.05.009
58. Wang G., Zhang Q., Zhao X., Dong H., Wu C., Wu F., Yu B., Lv J., Zhang S., Wu G., Wu S., Wang X., Wu Y., Zhong Y. Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study. Lipids Health Dis. 2020;19(1):204. doi: 10.1186/s12944-020-01382-9
59. Wei X., Zeng W., Su J., Wan H., Yu X., Cao X., Tan W., Wang H. Hypolipidemia is associated with the severity of COVID-19. J. Clin. Lipidol. 2020;14(3):297–304. doi: 10.1016/j.jacl.2020.04.008
60. Fan J., Wang H., Ye G., Cao X., Xu X., Tan W., Zhang Y. Letter to the editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. Metabolism. 2020;107:154243. doi: 10.1016/j.metabol.2020.154243
61. Aparisi Á., Iglesias-Echeverría C., Ybarra-Falcón C., Cusácovich I., Uribarri A., García-Gómez M., Ladrón R., Fuertes R., Candela J., Tobar J., … Andaluz-Ojeda D. Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19. Nutr. Metab. Cardiovasc. Dis. 2021;31(9):2619–2627. doi: 10.1016/j.numecd.2021.06.016
62. Dobiasova M., Frohlich J., Sedova M., Cheung M.C., Brown B.G. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J. Lipid Res. 2011;52(3):566–571. doi: 10.1194/jlr.P011668
63. Onat A., Can G., Kaya H., Hergenç G. «Atherogenic index of plasma» (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J. Clin. Lipidol. 2010;4(2):89–98. doi: 10.1016/j.jacl.2010.02.005
64. Yildiz G., Duman A., Aydin H., Yilmaz A., Hür E., Mağden K., Cetin G., Candan F. Evaluation of association between atherogenic index of plasma and intima-media thickness of the carotid artery for subclinic atherosclerosis in patients on maintenance hemodialysis. Hemodial. Int. 2013;7(3):397–405. doi: 10.1111/hdi.12041
65. Niroumand S., Khajedaluee M., Khadem-Rezaiyan M., Abrishami M., Juya M., Khodaee G., Dadgar-moghaddam M. Atherogenic index of plasma (AIP): A marker of cardiovascular disease. Med. J. Islam. Repub. Iran. 2015;29:240.
66. Turgay Yıldırım Ö., Kaya Ş. The atherogenic index of plasma as a predictor of mortality in patients with COVID-19. Heart Lung. 2021;50(2):329–333. doi: 10.1016/j.hrtlng.2021.01.016
Review
Views:
88314
Email this article 